Shelley J Allen
Affiliation: University of Bristol
- TrkAd5: A novel therapeutic agent for treatment of inflammatory pain and asthmaJudy J Watson
Molecular Neurobiology Unit, Henry Wellcome Laboratories for Integrative Neuroscience and Endocrinology, Bristol, UK
J Pharmacol Exp Ther 316:1122-9. 2006..We conclude that TrkAd5 will prove effective in ameliorating both acute and chronic conditions where nerve growth factor acts as a mediator and suggest a role for its application in vivo as a novel therapeutic...
- NGF receptor TrkAd5: therapeutic agent and drug design targetD Dawbarn
Department of Medicine, University of Bristol, Bristol BS1 3NY, UK
Biochem Soc Trans 34:587-90. 2006..In addition, TrkAd5 has been shown to be efficacious in preclinical models of inflammatory pain and asthma by the sequestration of excess levels of endogenous NGF, and therefore represents a novel therapeutic agent...
- Human ProNGF: biological effects and binding profiles at TrkA, P75NTR and sortilinOliver Clewes
Henry Wellcome Laboratories for Integrative Neuroscience and Endocrinology, University of Bristol, Bristol, UK
J Neurochem 107:1124-35. 2008..Our data show that M-proNGF stimulates TrkA to a lesser degree than NGF, suggesting that in Alzheimer brain the increased proNGF : NGF and p75(NTR) : TrkA ratios may permit apoptotic effects to predominate over neurotrophic effects...
- The neurotrophins and their role in Alzheimer's diseaseShelley J Allen
Dorothy Hodgkin Building, School of Clinical Sciences, University of Bristol, Bristol BS1 3NY, UK
Curr Neuropharmacol 9:559-73. 2011..In addition, the possibilities of neurotrophin-based therapeutics are evaluated...
- GDNF, NGF and BDNF as therapeutic options for neurodegenerationShelley J Allen
Dorothy Hodgkin Building, Whitson St, Bristol BS1 3NY, UK
Pharmacol Ther 138:155-75. 2013..We evaluate these neurotrophic factors as potential short or long-term treatments, weighing up preclinical and clinical results with the possible effects on the underlying neurodegenerative process...
- Recombinant human nerve growth factor for clinical trials: protein expression, purification, stability and characterisation of binding to infusion pumpsS J Allen
Molecular Neurobiology Unit, University Research Centre for Neuroendocrinology Care of the Elderly, University of Bristol, BS2 8HW, Bristol, UK
J Biochem Biophys Methods 47:239-55. 2001..Tests were also carried out to monitor release of protein from infusion pumps and catheters for intracerebroventricular administration (icv). Initial problems with non-specific binding were overcome using a blocking formula...
- Clinical relevance of the neurotrophins and their receptorsShelley J Allen
University of Bristol, Dorothy Hodgkin Building, Bristol BS1 3NY, UK
Clin Sci (Lond) 110:175-91. 2006..Ways in which the neurotrophins, their receptors or agonists/antagonists may act therapeutically are discussed...
- Targeting nerve growth factor in pain: what is the therapeutic potential?Judy J Watson
University of Bristol, Bristol, UK
BioDrugs 22:349-59. 2008..Other possible future therapies examined in this review include small-molecule TrkA antagonists, which target either the extracellular NGF binding domain of TrkA or its intracellular tyrosine kinase domain...
- Profound and selective loss of catalytic TrkB immunoreactivity in Alzheimer's diseaseS J Allen
Molecular Neurobiology Unit, Department of Medicine Care of the Elderly, University of Bristol, Bristol Royal Infirmary, Bristol, BS2 8HW, United Kingdom
Biochem Biophys Res Commun 264:648-51. 1999..This may have important consequences for the neurotrophic support of vulnerable neurons in AD...
- Neurotrophins and neurodegenerationD Dawbarn
University of Bristol, Bristol Royal Infirmary, Bristol, UK
Neuropathol Appl Neurobiol 29:211-30. 2003....
- In vitro studies of membrane protein foldingP J Booth
Department of Biochemistry, School of Medical Sciences, University Walk, Bristol, UK
Crit Rev Biochem Mol Biol 36:501-603. 2001..With this in mind, we also cover some relevant properties of model, lipid-bilayer systems...
- Can we identify the forces that drive the folding of integral membrane proteins?P J Booth
Department of Biochemistry, University of Bristol, University Walk, Bristol BS8 1TD, UK
Biochem Soc Trans 29:408-13. 2001..These are generic properties of the bilayer that can be achieved with simple mixtures of many types of biological lipid and seem to be important in vivo...
- Identification and structure of the nerve growth factor binding site on TrkAA G Robertson
Molecular Neurobiology Unit, URCN, Bristol, BS2 8HW, United Kingdom
Biochem Biophys Res Commun 282:131-41. 2001..We also present the three-dimensional structure of the TrkAIg(2) domain in a new crystal form, refined to 2.0 A resolution...
- Identification of syntaxin 1A as a novel binding protein for presenilin-1S K Smith
Molecular Neurobiology Unit, Department of Medicine Care of the Elderly, University of Bristol, Bristol, BS2 8HW, UK
Brain Res Mol Brain Res 78:100-7. 2000..In vitro experiments confirm the two-hybrid results suggesting that PS1 binds syntaxin under physiological conditions...
- Production of an activated form of Bacillus stearothermophilus L-2-hydroxyacid dehydrogenase by directed evolutionS J Allen
Molecular Recognition Centre, Department of Biochemistry, School of Medical Sciences, University of Bristol, University Walk, Bristol BS8 1TD, UK
Protein Eng 13:5-7. 2000..What is significant is the activation of bsLDH by a subtle long range event produced by the 'blind' directed evolution approach...
- alpha- and beta-secretase: profound changes in Alzheimer's diseaseSusan J Tyler
Molecular Neurobiology Unit, URCN Care of the Elderly University of Bristol, Bristol Royal Infirmary, Bristol, UK
Biochem Biophys Res Commun 299:373-6. 2002..Eighty percent of Alzheimer brains examined had an increase in beta-secretase, a decrease in alpha-secretase, or both; which may account for the means by which the majority of people develop Alzheimer's disease...
- Stepwise, non-adherent differentiation of human pluripotent stem cells to generate basal forebrain cholinergic neurons via hedgehog signalingLucy A Crompton
Henry Wellcome Laboratory for Integrative Neuroscience and Endocrinology, School of Clinical Sciences, University of Bristol, Dorothy Hodgkin Building, Whitson Street, Bristol BS1 3NY, UK
Stem Cell Res 11:1206-21. 2013..In conclusion, this work provides a renewable source of human functional bfCNs applicable for studying AD specifically in the cholinergic system, and also provides a model of the key embryonic events in human bfCN development. ..
- A discrete domain of the human TrkB receptor defines the binding sites for BDNF and NT-4Ruth L Naylor
University Research Centre for Neuroendocrinology Care of the Elderly, Bristol Royal Infirmary, Bristol, BS2 8HW, United Kingdom
Biochem Biophys Res Commun 291:501-7. 2002..It is hoped that the understanding of specific interactions will allow design of small molecule neurotrophin mimetics...
- Premorbid effects of APOE on synaptic proteins in human temporal neocortexSeth Love
Department of Neuropathology, University of Bristol Institute of Clinical Neurosciences, Frenchay Hospital, Bristol BS16 1LE, UK
Neurobiol Aging 27:797-803. 2006..01). APOE influences the concentration of synaptic proteins in normal superior temporal cortex and may thereby affect the response to injury, and the risk and outcome of a range of neurologic diseases...